CD276 - Wikipedia
Cluster of Differentiation 276 (CD276) or B7 Homolog 3 (B7-H3) is a human protein encoded by the CD276 gene. [5] B7-H3 is a 316 amino acid-long type I transmembrane protein, existing in …
B7-H3, a checkpoint molecule, as a target for cancer …
Mar 20, 2022 · As a newly identified member of the B7 family 3, B7-H3 could promote the activation of T cells and the proliferation of IFN-γ. In this review, we summarized research in …
Tumor Immunotherapy Targeting B7-H3: From Mechanisms to …
In addition, B7-H3 promotes tumor cell proliferation, migration, invasion, metabolism disorder, angiogenesis, and resistance to treatment to promote tumor progression through its non …
B7-H3: An Attractive Target for Antibody-based Immunotherapy
Mar 1, 2021 · In nonmalignant tissues, B7-H3 has a predominantly inhibitory role in adaptive immunity, suppressing T-cell activation and proliferation. In malignant tissues, B7-H3 inhibits …
New frontiers in immune checkpoint B7-H3 (CD276) research and …
B7-H3 (CD276), a member of the B7 family of proteins, is a key player in cancer progression. This immune checkpoint molecule is selectively expressed in both tumor cells and immune cells …
Immune checkpoint of B7-H3 in cancer: from immunology to …
Oct 25, 2022 · In this review, we summarize the emerging research on the function and underlying pathways of B7-H3, the expression and roles of B7-H3 in different cancer types, …
B7-H3: an attractive target for antibody-based immunotherapy
In non-malignant tissues, B7-H3 has a predominantly inhibitory role in adaptive immunity, suppressing T-cell activation and proliferation. In malignant tissues, B7-H3 inhibits tumor …
Targeting site-specific N-glycosylated B7H3 induces potent
3 days ago · Article CAS PubMed Google Scholar Chen, H. et al. EBV-upregulated B7-H3 inhibits nk cell-mediated antitumor function and contributes to nasopharyngeal carcinoma progression. …
B7-H3 as a Dual Clinically Relevant Checkpoint and Antibody Drug ...
Jan 24, 2025 · B7-H3 has recently emerged as a promising clinical target for immunotherapy in the localized setting and antibody drug targeting in the metastatic setting.
B7-H3: a robust target for immunotherapy in prostate cancer
Jun 4, 2024 · B7-H3, an immune checkpoint glycoprotein, facilitates immune evasion and the promotion of tumors and is highly expressed on the surface of prostate cancer (PCa) cells, …
- Some results have been removed